Smith Asset Management Group LP cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.3% during the second quarter, Holdings Channel reports. The firm owned 26,980 shares of the biopharmaceutical company’s stock after selling 1,200 shares during the period. Smith Asset Management Group LP’s holdings in Halozyme Therapeutics were worth $346,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Karp Capital Management Corp bought a new position in Halozyme Therapeutics during the first quarter valued at about $188,000. LLBH Private Wealth Management LLC bought a new position in Halozyme Therapeutics during the first quarter valued at about $2,021,000. Pictet Asset Management Ltd. bought a new position in Halozyme Therapeutics during the first quarter valued at about $18,888,000. Bank of New York Mellon Corp boosted its position in Halozyme Therapeutics by 27.3% in the first quarter. Bank of New York Mellon Corp now owns 1,806,490 shares of the biopharmaceutical company’s stock valued at $23,412,000 after buying an additional 387,486 shares during the period. Finally, Chicago Equity Partners LLC boosted its position in Halozyme Therapeutics by 1.7% in the first quarter. Chicago Equity Partners LLC now owns 170,030 shares of the biopharmaceutical company’s stock valued at $2,204,000 after buying an additional 2,770 shares during the period. Institutional investors and hedge funds own 81.09% of the company’s stock.
Shares of Halozyme Therapeutics, Inc. (NASDAQ HALO) opened at 12.05 on Tuesday. The company’s 50-day moving average is $13.04 and its 200-day moving average is $13.14. Halozyme Therapeutics, Inc. has a one year low of $8.18 and a one year high of $15.20. The company’s market capitalization is $1.61 billion.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm earned ($0.21) earnings per share. Equities analysts predict that Halozyme Therapeutics, Inc. will post ($0.97) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/08/15/halozyme-therapeutics-inc-nasdaqhalo-position-lowered-by-smith-asset-management-group-lp.html.
Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Barclays PLC reiterated an “overweight” rating and issued a $16.00 price objective on shares of Halozyme Therapeutics in a report on Friday, June 23rd. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 12th. Canaccord Genuity set a $16.00 target price on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 26th. Finally, BMO Capital Markets began coverage on shares of Halozyme Therapeutics in a report on Monday, April 17th. They set a “market perform” rating and a $14.00 target price for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $14.75.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
What are top analysts saying about Halozyme Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Halozyme Therapeutics Inc. and related companies.